Neurons expressing glutamate ionotropic kainate receptor subunit 2 (GluK2, formerly KAR2), the predominant kainate receptor (KAR) in the mammalian brain. GluK2-containing KARs are ionotropic glutamate receptors that mediate slow excitatory neurotransmission and modulate synaptic plasticity throughout the central nervous system.
Kainate receptors are tetrameric assemblies composed of five subunits (GluK1-GluK5), with GluK2 forming homomeric or heteromeric channels that conduct Na⁺ and K⁺ currents. The GluK2 subunit determines key pharmacological and biophysical properties of the receptor complex, including gating kinetics, conductance, and sensitivity to agonists and antagonists.
¶ Molecular Biology and Structure
The GRIK2 gene (glutamate ionotropic kainate receptor subunit 2) encodes the GluK2 protein, which consists of:
- N-terminal domain (ATD): extracellular agonist-binding domain involved in subunit assembly and allosteric modulation
- Ligand-binding domain (LBD): twoushiell domains (S1 and S2) that bind glutamate and kainate
- Transmembrane domain (TMD): three membrane-spanning helices (M1-M3) forming the ion channel pore
- C-terminal domain (CTD): intracellular region involved in protein interactions and trafficking
GluK2 undergoes extensive alternative splicing, producing multiple isoforms with distinct trafficking properties and functional characteristics. Post-translational modifications including phosphorylation, glycosylation, and SUMOylation regulate receptor localization and function.
GluK2-expressing neurons are prominently distributed in:
- CA3 region: Highest density of GluK2-containing KARs, particularly on mossy fiber terminals
- CA1 stratum radiatum: Modulates Schaffer collateral-CA1 synaptic transmission
- Dentate gyrus: Regulates granule cell excitability and pattern separation
- Purkinje cells: GluK2 contributes to cerebellar motor learning and coordination
- Granule cells: Express GluK2 as part of heteromeric receptors
- Molecular layer: Modulates parallel fiber-Purkinje cell signaling
- Layer II/III pyramidal neurons: Express GluK2 in cortical microcircuits
- Interneurons: Various GABAergic populations express GluK2
- Temporal cortex: High expression in regions relevant to memory and AD pathology
- Amygdala: Modulates fear conditioning and emotional memory
- Thalamus: Sensory relay nuclei contain GluK2-expressing neurons
- Basal ganglia: Moderate expression in striatum and substantia nigra
GluK2-containing kainate receptors exhibit distinctive electrophysiological characteristics:
- Activation: Slow rise time (~10-20 ms to peak)
- Desensitization: Incomplete desensitization with sustained current component
- Deactivation: Rapid closure upon agonist removal
- Predominantly Na⁺ permeable with moderate K⁺ permeability
- Calcium permeability varies with subunit composition
- Voltage-dependent magnesium block at negative potentials
- Agonists: Kainate (full agonist), glutamate (endogenous), ATPA (GluK1-selective)
- Antagonists: LY466365 (GluK1 antagonist), UBP310 (broad-spectrum)
- Modulators: Concanavalin A (potentiates desensitization), MTSEA (cysteine modifier)
¶ Synaptic Function and Transmission
GluK2 neurons participate in diverse forms of synaptic transmission:
- Located on presynaptic terminals where they regulate neurotransmitter release
- Modulate GABA release from interneurons
- Control glutamate release from mossy fibers in hippocampus
- Activity-dependent modulation of short-term plasticity
- Generate slow excitatory postsynaptic potentials (EPSPs)
- Contribute to neuronal integration and dendritic excitability
- Shape action potential timing and burst firing
- Modulate gamma (30-80 Hz) and theta (4-8 Hz) oscillations
- Influence hippocampal place cell firing
- Regulate hippocampal sharp waves and ripples
Although primarily ionotropic, GluK2 engages in metabotropic signaling:
- Direct Na⁺ influx activates voltage-gated calcium channels
- Membrane depolarization removes NMDA receptor Mg²⁺ block
- Triggered intracellular cascades include CaMKII activation
- PSD-95: Anchors GluK2 at postsynaptic densities
- GRIP/GRIP1: Scaffolding protein linking GluK2 to other receptors
- RACK1: Regulates receptor trafficking and degradation
- Akt/mTOR pathway: Linked to synaptic plasticity mechanisms
- MAPK/ERK signaling cascade
- CREB-mediated gene transcription
- Synaptic protein synthesis regulation
GluK2-containing kainate receptors are implicated in multiple aspects of AD pathophysiology:
Amyloid-Beta Interactions
- Aβ oligomers enhance GluK2-mediated currents
- Alters KAR-dependent synaptic plasticity in hippocampus
- Contributes to excitotoxicity in cortical neurons
Tau Pathology
- Tau phosphorylation affects GluK2 trafficking
- Loss of GluK2 from synapses correlates with cognitive decline
- DysregulatedKAR signaling exacerbates tau-induced neurodegeneration
Therapeutic Implications
- KAR antagonists show promise in preclinical AD models
- Targeting GluK2 may restore synaptic function
- Gene therapy approaches to modulate GRIK2 expression under investigation
Motor Neuron Vulnerability
- Altered GluK2 expression in spinal motor neurons
- Excitotoxic mechanisms contribute to ALS progression
- Dysregulated glutamate transport amplifies KAR-mediated toxicity
Non-Cell Autonomous Effects
- Astrocytic GRIK2 expression affects motor neuron survival
- Microglial KARs modulate neuroinflammation
Seizure Genesis
- GRIK2 mutations associated with epileptic encephalopathy
- Enhanced GluK2 function promotes hyperexcitability
- Mossy fiber sprouting increases KAR-mediated excitation
Therapeutic Targeting
- KAR antagonists demonstrate anticonvulsant properties
- Gene therapy to reduce GluK2 expression being explored
- GRIK2⁻/⁻ mice exhibit altered hippocampal plasticity
- Reduced seizure threshold in some backgrounds
- Behavioral phenotypes including anxiety and social deficits
- Overexpression of GluK2 increases excitability
- Human GRIK2 mutations introduced to model epilepsy
- Conditional knockout allows temporal control of deletion
- KAR antagonists: Neuroprotective in preclinical models
- Positive allosteric modulators: Potential for cognitive enhancement
- Subunit-selective compounds: Greater therapeutic precision
- CRISPR-based approaches to correct disease mutations
- RNA interference to reduce toxic gain-of-function
- Viral vector delivery to specific brain regions
- GRIK2 expression as potential disease biomarker
- CSF levels of GluK2 in neurodegenerative disease patients
- Kainate receptors in synaptic function and epilepsy (2019)
- Kainate receptors in neurological disorders (2020)
- GluK2 receptor structure and function (2018)
- Kainate receptors in Alzheimer's disease (2021)
- KAR modulation of hippocampal oscillations (2019)
- GluK2 and excitotoxicity in ALS (2020)
- Therapeutic targeting of KARs (2021)
- GRIK2 mutations in epileptic encephalopathy (2018)